The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor
Blocking the tyrosine kinase cell-cycle progression regulator WEE1 may help to reinstate tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors
Novel scheduling of RP-3500 mitigates haematological toxicity and may facilitate combination therapy but tumour types most likely to respond remain to be defined
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Early-phase trials suggest that sitravatinib may reboot the tumour response to PD-1 inhibitors, but confirmation of efficacy is required and strategies are needed to adjust tolerability
Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Over the last decade, much progress has been made in developing a range of antibody–drug conjugates to treat breast cancer, with the construction of bespoke agents for individual patients and exciting prospect for the future
In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.